Neurobiology and Evidence-Based Review on Novel Therapeutic Strategy for Treatment-Resistant Depression (TRD)

Chapter

Abstract

Treatment refractory depression (TRD) causes more burden although newer antidepressants have been introduced in last decades. In this chapter, the authors will discuss the novel treatment approaches based upon new neurobiological models and review the evidence-based treatments. Special consideration will be given to the inflammation hypothesis, ketamine, ECT, and deep brain stimulation.

Keywords

Treatment-resistant depression Neuroinflammation Electroconvulsive therapy Deep brain stimulation Ketamine 

References

  1. Anderson IM, Blamire A, Branton T, Brigadoi S, Clark R, Downey D, et al. Efficacy and mechanism evaluation randomised controlled trial of ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (ketamine-ECT study). Southampton: NIHR Journals Library; 2017.Google Scholar
  2. Bauer M, Ströhle A. Behandlungsstrategien bei prophylaxeresistenten bipolaren Störungen. Nervenarzt. 1999;70(7):587–99.CrossRefGoogle Scholar
  3. Berlim MT, Turecki G. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol. 2007;17(11):696–707.CrossRefGoogle Scholar
  4. Best MW, Fitzpatrick M, Milev R, Bowie CR, Jokic R. Utility of the berlin questionnaire for predicting obstructive sleep apnea in individuals with treatment-resistant depression. Sleep Breath. 2013;17(4):1221–7.CrossRefGoogle Scholar
  5. Birmaher B, Axelson D, Goldstein B, Strober M, Gill MK, Hunt J, et al. Four-year longitudinal course of children and adolescents with bipolar spectrum disorders: the Course and Outcome of Bipolar Youth (COBY) Study. Focus. 2012;10(3):389–400.CrossRefGoogle Scholar
  6. Bryson EO, Kellner CH. Ketamine anesthesia for electroconvulsive therapy. Psychiatr Times. 2014;31(5):38.Google Scholar
  7. Caddy C, Amit BH, McCloud TL, Rendell JM, Furukawa TA, McShane R, et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev. 2015;9.Google Scholar
  8. Conca A, König P, Hausmann A. Transcranial magnetic stimulation induces ‘pseudoabsence seizure’. Acta Psychiatr Scand. 2000;101(3):246–9.CrossRefGoogle Scholar
  9. Coppen A, Abou-Saleh M, Milln P, Metcalfe M, Harwood J, Bailey J. Dexamethasone suppression test in depression and other psychiatric illness. Br J Psychiatry. 1983;142(5):498.CrossRefGoogle Scholar
  10. Cretaz E, Brunoni AR, Lafer B. Magnetic seizure therapy for unipolar and bipolar depression: a systematic review. Neural Plast. 2015;2015:1–9.CrossRefGoogle Scholar
  11. Cusin C, Iovieno N, Iosifescu DV, Nierenberg AA, Fava M, Rush AJ, et al. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. J Clin Psychiatry. 2013;74(7):e636–41.CrossRefGoogle Scholar
  12. Delgado PL. Depression: the case for a monoamine deficiency. J Clin Psychiatry. 2000;61(Suppl 6):7–11.PubMedPubMedCentralGoogle Scholar
  13. DeWilde KE, Levitch CF, Murrough JW, Mathew SJ, Iosifescu DV. The promise of ketamine for treatment-resistant depression: current evidence and future directions. Ann N Y Acad Sci. 2015;1345:47–58.CrossRefGoogle Scholar
  14. Dougherty DD, Rezai AR, Carpenter LL, Howland RH, Bhati MT, O’Reardon JP, et al. A randomized sham-controlled trial of deep brain stimulation of the ventral capsule/ventral striatum for chronic treatment-resistant depression. Biol Psychiatry. 2015;78(4):240–8.CrossRefGoogle Scholar
  15. Fenoy AJ, Schulz P, Selvaraj S, Burrows C, Spiker D, Cao B, et al. Deep brain stimulation of the medial forebrain bundle: distinctive responses in resistant depression. J Affect Disord. 2016;203:143–51.CrossRefGoogle Scholar
  16. Goodwin G, Haddad P, Ferrier I, Aronson J, Barnes T, Cipriani A, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30(6):495–553.CrossRefGoogle Scholar
  17. Gorwood P, Rouillon F, Even C, Falissard B, Corruble E, Moran P. Treatment response in major depression: effects of personality dysfunction and prior depression. Br J Psychiatry. 2010;196(2):139–42.CrossRefGoogle Scholar
  18. Gould TD, Zanos P, Zarate CA Jr. Ketamine mechanism of action: separating the wheat from the chaff. Neuropsychopharmacology. 2017;42(1):368–9.CrossRefGoogle Scholar
  19. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller H-J, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010;11(2):81–109.CrossRefGoogle Scholar
  20. Hassan AK, Farmer KC, Brahm NC, Neas BR. Evaluating antidepressant treatment prior to adding second-line therapies among patients with treatment-resistant depression. Int J Clin Pharm. 2016;38(2):429–37.CrossRefGoogle Scholar
  21. Hirschfeld R, Bowden CL, Gitlin MJ, Keck PE, Suppes T, Thase ME, et al. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry. 2002;159(44 Suppl):1–50.Google Scholar
  22. Hirschfeld RM. Guidelines for the long-term treatment of depression. J Clin Psychiatry. 1994;55:61–9. discussion 70-61PubMedGoogle Scholar
  23. Hirschfeld RM. Guideline watch: practice guideline for the treatment of patients with bipolar disorder. Arlington: American Psychiatric Association; 2005.Google Scholar
  24. Iosifescu DV, Bankier B, Fava M. Impact of medical comorbid disease on antidepressant treatment of major depressive disorder. Curr Psychiatry Rep. 2004;6(3):193–201.CrossRefGoogle Scholar
  25. Bauer IE, Soares JC, Selek S, Meyer TD. Volume editors: a volume in the series. The link between refractoriness and neuroprogression in treatment-resistant bipolar disorder. In: Halaris BLGA (Chicago), editors. Modern trends in pharmacopsychiatry (vol. neuroprogression in psychiatric disorders). Basel: Karger Publishers; 2016.Google Scholar
  26. Jarventausta K, Sorri A, Kampman O, Bjorkqvist M, Tuohimaa K, Hamalainen M, et al. Changes in interleukin-6 levels during electroconvulsive therapy may reflect the therapeutic response in major depression. Acta Psychiatr Scand. 2017;135(1):87–92.CrossRefGoogle Scholar
  27. Keitner GI, Mansfield AK. Management of treatment-resistant depression. Psychiatr Clin North Am. 2012;35(1):249–65.CrossRefGoogle Scholar
  28. Kornstein SG, Schneider RK. Clinical features of treatment-resistant depression. J Clin Psychiatry. 2001;62(Suppl 16):18.PubMedGoogle Scholar
  29. Krupitsky EM, Burakov AM, Dunaevsky IV, Romanova TN, Slavina TY, Grinenko AY. Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs. 2007;39(1):13.CrossRefGoogle Scholar
  30. Kubitz N, Mehra M, Potluri RC, Garg N, Cossrow N. Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database. PLoS One. 2013;8(10):e76882.CrossRefGoogle Scholar
  31. Lally N, Nugent AC, Luckenbaugh DA, Niciu MJ, Roiser JP, Zarate CA. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J Psychopharmacol. 2015;29(5):596–607.CrossRefGoogle Scholar
  32. Lepine BA, Moreno RA, Campos RN, Couttolenc BF. Treatment-resistant depression increases health costs and resource utilization. Rev Bras Psiquiatr. 2012;34(4):379–88.CrossRefGoogle Scholar
  33. Liu CS, Carvalho AF, McIntyre RS. Towards a “metabolic” subtype of major depressive disorder: shared pathophysiological mechanisms may contribute to cognitive dysfunction. CNS Neurol Disord Drug Targets. 2014;13(10):1693–707.CrossRefGoogle Scholar
  34. Machado-Vieira R, Salvadore G, Diazgranados N, Zarate CA Jr. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther. 2009;123(2):143–50.CrossRefGoogle Scholar
  35. Maher DP, Chen L, Mao J. Intravenous ketamine infusions for neuropathic pain management: a promising therapy in need of optimization. Anesth Analg. 2017;124(2):661–74.CrossRefGoogle Scholar
  36. Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, et al. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45(5):651–60.CrossRefGoogle Scholar
  37. Micallef-Trigona B. Comparing the effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in the treatment of depression: a systematic review and meta-analysis. Depress Res Treat. 2014;2014:135049.PubMedPubMedCentralGoogle Scholar
  38. Milev RV, Giacobbe P, Kennedy SH, Blumberger DM, Daskalakis ZJ, Downar J, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 4. Neurostimulation treatments. Can J Psychiatr. 2016;61(9):561–75.CrossRefGoogle Scholar
  39. Nierenberg AA, Petersen TJ, Alpert JE. Prevention of relapse and recurrence in depression: the role of long-term pharmacotherapy and psychotherapy. J Clin Psychiatry. 2003;64(Suppl 15):13–7.PubMedGoogle Scholar
  40. Pacchiarotti I, Mazzarini L, Colom F, Sanchez-Moreno J, Girardi P, Kotzalidis GD, et al. Treatment-resistant bipolar depression: towards a new definition. Acta Psychiatr Scand. 2009;120(6):429–40.CrossRefGoogle Scholar
  41. Passione R. Italian psychiatry in an international context: Ugo Cerletti and the case of electroshock. Hist Psychiatry. 2004;15(1):83–104.CrossRefGoogle Scholar
  42. Pollack MH. Comorbid anxiety and depression. J Clin Psychiatry. 2005;66(Suppl 8):22–9.PubMedGoogle Scholar
  43. Post T, Kemmler G, Krassnig T, Brugger A, Hausmann A. Efficacy of continuation and maintenance electroconvulsive therapy (c/m ECT) in the treatment of patients with therapy-resistant affective disorders: a retrospective analysis. Neuropsychiatrie. 2015;29(3):133.CrossRefGoogle Scholar
  44. Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66(5):522–6.CrossRefGoogle Scholar
  45. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor-alpha antagonist infliximab in treatment resistant depression: role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31–41.CrossRefGoogle Scholar
  46. Ryan KM, Glaviano A, O’Donovan SM, Kolshus E. Electroconvulsive therapy modulates plasma pigment epithelium-derived factor in depression: a proteomics study. Transl Psychiatry. 2017;7(3):e1073.CrossRefGoogle Scholar
  47. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62(Suppl 16):10–7.PubMedGoogle Scholar
  48. Sanacora G, Heimer H, Hartman D, Mathew SJ, Frye M, Nemeroff C, et al. Balancing the promise and risks of ketamine treatment for mood disorders. Neuropsychopharmacology. 2017;42(6):1179–81.CrossRefGoogle Scholar
  49. Sasaki T, Hashimoto K, Oda Y, Ishima T, Yakita M, Kurata T, et al. Increased serum levels of oxytocin in “Treatment Resistant Depression in Adolescents (TRDIA)” Group. PLoS One. 2016;11(8):e0160767.CrossRefGoogle Scholar
  50. Schatzberg AF. A word to the wise about ketamine. Am J Psychiatry. 2014;171(3):262–4.CrossRefGoogle Scholar
  51. Schoeyen HK, Kessler U, Andreassen OA, Auestad BH, Bergsholm P, Malt UF, et al. Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment. Am J Psychiatry. 2015;172(1):41–51.CrossRefGoogle Scholar
  52. Selek S, Passos IC, Soares JC. The management of treatment resistance bipolar disorder. In: Carvalho AF, Vieta E, editors. The treatment of bipolar disorder. 1st ed. Oxford: Oxford University Press; 2017. p. 338–56.Google Scholar
  53. Shamseddeen W, Asarnow JR, Clarke G, Vitiello B, Wagner KD, Birmaher B, et al. Impact of physical and sexual abuse on treatment response in the Treatment of Resistant Depression in Adolescent Study (TORDIA). J Am Acad Child Adolesc Psychiatry. 2011;50(3):293–301.CrossRefGoogle Scholar
  54. Shiroma PR, Albott CS, Johns B, Thuras P, Wels J, Lim KO. Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. Int J Neuropsychopharmacol. 2014;17(11):1805–13.CrossRefGoogle Scholar
  55. Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173(8):816–26.CrossRefGoogle Scholar
  56. Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007;68(7):1062–70.CrossRefGoogle Scholar
  57. Souery D, Serretti A, Calati R, Oswald P, Massat I, Konstantinidis A, et al. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol. 2011;31(4):512–6.CrossRefGoogle Scholar
  58. The UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003;361(9360):799–808.CrossRefGoogle Scholar
  59. Torres-Sanchez S, Perez-Caballero L, Berrocoso E. Cellular and molecular mechanisms triggered by deep brain stimulation in depression: a preclinical and clinical approach. Prog Neuropsychopharmacol Biol Psychiatry. 2017;73:1–10.CrossRefGoogle Scholar
  60. Vaidya NA, Mahableshwarkar AR, Shahid R. Continuation and maintenance ECT in treatment-resistant bipolar disorder. J ECT. 2003;19(1):10–6.CrossRefGoogle Scholar
  61. Voineskos D, Levinson AJ, Sun Y, Barr MS, Farzan F, Rajji TK, et al. The relationship between cortical inhibition and electroconvulsive therapy in the treatment of major depressive disorder. Sci Rep. 2016;6:37461.CrossRefGoogle Scholar
  62. WHO Expert Committee on Drug Dependence. WHO Expert Committee on Drug Dependence: thirty-sixth report, vol. 991. Geneva: World Health Organization; 2015.Google Scholar
  63. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1–44.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Department of Psychiatry, McGovern Medical SchoolUniversity of Texas Health Science Center at HoustonHoustonUSA

Personalised recommendations